Guerbet adquiere Mallinckrodt.

Aiming to create a new global leader in medical imaging, Guerbet multinational announced that it had signed a definitive agreement under which it will acquire Contrast Media Systems and Business Administration from Mallinckrodt ("CMDS").

Guerbet is a company of French origin, a pioneer in the field of contrast media, with almost 90 years of experience in the global market, the only pharmaceutical group dedicated to the field of medical imaging worldwide. Offers a wide range of X-ray, magnetic resonance imaging (MRI), Interventional Radiology, injectors and medical devices related to improve the diagnosis and treatment of patients.

Mallinckrodt, in turn, is an American company, a global biopharmaceutical specializes in medical imaging business that develops, manufactures, markets and distributes specialty pharmaceuticals, contrast media and images.

Yves L'Epine, Guerbet CEO, commented on the business operation conducted by these multinationals: "This acquisition transforms and motorized Guerbets future: turnover doubles, can expand our geographic footprint and complement the offer both in contrast media and solutions and imaging services. We would be very pleased to welcome our colleagues CMDS Mallinckrodt to realize a successful and fast integration process and then start together the way to creating a new global leader in medical imaging ".

The acquisition also comes at a time of historic fortress of Guerbet. This company currently has a sound financial position and the rapid reduction of debt in the last three years, the Group is well positioned for best results in an operation of this magnitude.